Clinical Trials Browser

Withdrawn × ublituximab × Clear all

NCT05152459 2023-05-31

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoma, Follicular

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell